Market Overview

Wedbush Reiterates Outperform Rating on Omeros on Potential Increased OMS302 Use

Related OMER
Omeros Enters Overbought Territory - Tale Of The Tape
Omeros' Omidria Gets FDA Nod - Analyst Blog

In a report published Monday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Omeros Corporation (NASDAQ: OMER).

In the report, Wedbush noted, “A recent conversation with a high-volume cataract surgeon on OMS302's potential use enhances our outlook for Omeros. The FDA is cracking down on sterility of topical solutions used during intraocular lens replacement surgery. We recently had a conversation with a high-volume cataract surgeon about the changing regulatory landscape following sterility issues at compound pharmacies. The FDA has indicated that each patient must be given a separate bottle for topical NSAIDs and mydriatic agents. In addition, surgeons are no longer allowed to mix their own homebrews of these agents for use during surgery—a common practice.”

Omeros Corporation closed on Friday at $5.09.

Posted-In: Liana Moussatos WedbushAnalyst Color Reiteration Analyst Ratings


Related Articles (OMER)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters